Published in Chem Biol Drug Des on February 22, 2011
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov (2008) 4.66
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol (2005) 3.01
Anticancer and antiviral sulfonamides. Curr Med Chem (2003) 2.75
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
Activation of metabotropic glutamate receptor type 2/3 suppresses transmission at rat hippocampal mossy fibre synapses. J Physiol (1996) 2.34
Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med Res Rev (2003) 2.33
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res (2005) 2.10
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging (2005) 1.97
NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov (2005) 1.89
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A (1996) 1.70
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J (2006) 1.55
11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging (2003) 1.49
"Click, click, cyclize": a DOS approach to sultams utilizing vinyl sulfonamide linchpins. Org Lett (2009) 1.49
Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today (2007) 1.42
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem (2008) 1.39
Overview of prostate-specific membrane antigen. Rev Urol (2004) 1.34
Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med (2009) 1.31
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol (2009) 1.31
Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem (2004) 1.23
Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets (2009) 1.19
Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.09
The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.08
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem (2007) 1.08
Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase. Biochem Biophys Res Commun (2003) 1.02
Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett (2009) 1.00
Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm (2009) 0.99
Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography. Neurosci Lett (2005) 0.98
Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr D Biol Crystallogr (2007) 0.94
Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. Eur J Pharmacol (2009) 0.89
Antiviral sulfonamide derivatives. Mini Rev Med Chem (2004) 0.88
Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG. Ann N Y Acad Sci (1999) 0.81
Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications? Org Biomol Chem (2008) 0.80
Carbonic anhydrase inhibitors: aliphatic N-phosphorylated sulfamates--a novel zinc-anchoring group leading to nanomolar inhibitors. J Enzyme Inhib Med Chem (2004) 0.77
Monoclonal antibodies and prostate-specific membrane antigen. Curr Opin Investig Drugs (2004) 0.77
NAALADase inhibitors: A novel approach to glutamate regulation. Drug Discov Today (2000) 0.77
Capture and visualization of hydrogen sulfide by a fluorescent probe. Angew Chem Int Ed Engl (2011) 1.57
X-box binding protein 1 (XBP1s) is a critical determinant of Pseudomonas aeruginosa homoserine lactone-mediated apoptosis. PLoS Pathog (2013) 1.50
Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate (2012) 1.44
Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate (2008) 1.36
Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med (2009) 1.31
Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem (2004) 1.23
Triazolothienopyrimidine inhibitors of urea transporter UT-B reduce urine concentration. J Am Soc Nephrol (2012) 1.22
Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry (2008) 1.17
Global identification of peptidase specificity by multiplex substrate profiling. Nat Methods (2012) 1.14
Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif (2006) 1.13
Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J (2012) 1.10
Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol (2010) 1.09
Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.09
The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.08
Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol (2012) 1.06
Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett (2010) 1.06
A small molecule screen identifies selective inhibitors of urea transporter UT-A. Chem Biol (2013) 1.02
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett (2010) 1.01
In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen. Prostate (2009) 0.93
From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int J Oncol (2013) 0.92
A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. Prostate (2012) 0.91
PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. Prostate (2012) 0.91
Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium. Int J Oncol (2011) 0.89
Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen. Bioorg Med Chem (2005) 0.89
Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorg Med Chem Lett (2007) 0.88
Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen. Bioorg Med Chem Lett (2011) 0.88
Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells. Bioorg Med Chem Lett (2006) 0.88
High resolution time-of-flight mass analysis of the entire range of intact singly-charged proteins. Anal Chem (2011) 0.88
A Pt-cluster-based heterogeneous catalyst for homogeneous catalytic reactions: X-ray absorption spectroscopy and reaction kinetic studies of their activity and stability against leaching. J Am Chem Soc (2011) 0.87
Flow cytometric detection of prostate tumor cells using chemoaffinity labels. Prostate (2011) 0.84
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett (2012) 0.82
Stereoselective inhibition of glutamate carboxypeptidase by organophosphorus derivatives of glutamic acid. Bioorg Med Chem (2004) 0.82
Highly active heterogeneous palladium nanoparticle catalysts for homogeneous electrophilic reactions in solution and the utilization of a continuous flow reactor. J Am Chem Soc (2010) 0.82
CFTR inhibitors. Curr Pharm Des (2013) 0.81
Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. Bioorg Med Chem Lett (2012) 0.81
Fast drying of biocompatible polymer films loaded with poorly water-soluble drug nano-particles via low temperature forced convection. Int J Pharm (2013) 0.80
Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett (2007) 0.78
Small-molecule inhibitors of urea transporters. Subcell Biochem (2014) 0.78
The hydrazide/hydrazone click reaction as a biomolecule labeling strategy for M(CO)3 (M = Re, (99m)Tc) radiopharmaceuticals. Chem Commun (Camb) (2011) 0.78
Nordihydroguaiaretic acid inhibits transforming growth factor beta type 1 receptor activity and downstream signaling. Eur J Pharmacol (2009) 0.78
Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer. Bioconjug Chem (2014) 0.78
Impact of hydration state and molecular oxygen on the chemical stability of levothyroxine sodium. Pharm Dev Technol (2013) 0.77
High-performance liquid chromatography method for detecting prostate-specific membrane antigen activity. Anal Biochem (2002) 0.77
A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4. J Biol Chem (2012) 0.77
Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R). Bioorg Med Chem (2010) 0.76
Correction: X-Box Binding Protein 1 (XBP1s) Is a Critical Determinant of Pseudomonas aeruginosa Homoserine Lactone-Mediated Apoptosis. PLoS Pathog (2016) 0.75
Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells. Prostate (2014) 0.75
Metal-Ligand Multiple Bonding in Thorium-Phosphorus and -Arsenic Complexes. Chemistry (2017) 0.75
Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors. Chem Biol Drug Des (2013) 0.75